Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;38(4):893-897.
doi: 10.1038/s41375-024-02215-9. Epub 2024 Mar 12.

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Daniela Žáčková #  1 , Lukáš Semerád #  2 , Edgar Faber  3 , Hana Klamová  4 , Lukáš Stejskal  5 , Petra Bělohlávková  6 , Michal Karas  7 , Eduard Cmunt  8 , Olga Černá  9 , Jiřina Procházková  2 , Petra Čičátková  2 , Anežka Kvetková  2 , Tomáš Horňák  2 , Ivana Skoumalová  3 , Dana Srbová  4 , Cyril Šálek  4 , David Buffa  5 , Jaroslava Voglová  6 , Tomáš Jurček  2 , Adam Folta  2 , Ivana Ježíšková  2 , Hana Žižková  4 , Kateřina Machová Poláková  4 , Tomáš Papajík  3 , Pavel Žák  6 , Pavel Jindra  7 , Adam Svobodník  10 , Radka Štěpánová  10 , Jiří Mayer  2   11
Affiliations

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Daniela Žáčková et al. Leukemia. 2024 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

DŽ served as a member of advisory board for Novartis, served on a speaker’s bureau for Novartis, Pfizer and Angelini, served as a consultant for Novartis and Angelini, and received travel grants from Novartis, Pfizer, Angelini and Astra Zeneca. LSe received travel grant from Novartis and Angelini. EF served as a member of advisory board for Novartis and Zentiva, served on a speaker’s bureau for Novartis, Zentiva, and Angelini, participated in an expert opinion panel for Pearls Health Cyber, and received travel support from ELN Foundation and Altium International. PČ served as a consultant for Novartis and received travel support from Novartis and Angelini. TH served on a speaker’s bureau for Novartis, served as a consultant for Angelini, and received travel grant from Novartis. PJ served as a member of advisory board for Novartis, Astra Zeneca, Takeda, and Bristol-Myers Squibb, and received travel grants from Novartis, Astra Zeneca, and MSD. JM received research support from Novartis, Bristol-Myers Squibb, and Pfizer. Other authors declare no competing interests.

Figures

Fig. 1
Fig. 1. The Anti-HALF survey results.
A Patients’ perceptions regarding treatment-free remission (TFR) proposal. B Main reasons for the decision to not stop tyrosine kinase inhibitors (TKI) in the frame of the HALF trial.
See this image and copyright information in PMC

References

    1. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. doi: 10.1038/s41375-020-0776-2. - DOI - PMC - PubMed
    1. Sharf G, Marin C, Bradley JA, Pemberton-Whiteley Z, Bombaci F, Christensen RIO, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020;34:2102–12. doi: 10.1038/s41375-020-0867-0. - DOI - PMC - PubMed
    1. Sanford D, Kyle R, Lazo-Langner A, Xenocostas A, Chin-Yee I, Howson-Jan K, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol. 2014;21:e241–9. doi: 10.3747/co.21.1736. - DOI - PMC - PubMed
    1. Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res. 2015;39:1055–9. doi: 10.1016/j.leukres.2015.07.004. - DOI - PubMed
    1. Jiang Q, Liu ZC, Zhang SX, Gale RP. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2016;142:1539–47. doi: 10.1007/s00432-016-2159-7. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources